Zoledronic Acid and renal toxicity: data from French adverse effect reporting database.
about
The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.Severe polyarthritis secondary to zolendronic acid: a case report and literature reviewBisphosphonates and bone fractures in long-term kidney transplant recipientsTolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.Acute kidney injury and bisphosphonate use in cancer: a report from the research on adverse drug events and reports (RADAR) projectThe effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma.The kidney in oncology.International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.Prolonged recovery time from zoledronic Acid induced acute tubular necrosis: a case report and review of the literature.Management of bone disease in multiple myeloma.Ibandronate for the prevention of bone loss after allogeneic stem cell transplantation for hematologic malignancies: a randomized-controlled trial.Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity.Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.Renal Safety and Pharmacokinetics of Ibandronate in Multiple Myeloma Patients With or Without Impaired Renal Function
P2860
Q35584866-E6BAAD8B-17AA-4030-9BCA-BF3A8C97C858Q35747575-86F1F9E4-FDBB-4220-872A-813249E5CE17Q36606360-F96C6E7A-489C-4ED0-BF50-0DE449768818Q36674172-6685DDF1-3106-4292-BFA6-7F15EE17C63DQ36678173-31C4F7F3-2BC0-4FCE-9FCC-F64B5A6DFDCBQ36870585-3A713C4E-0E7B-40EE-A664-6C644152BAB9Q36900332-1DC868E0-A124-4C3B-B44F-C01CB8E4B11CQ36929923-5CF49FCC-A228-4E5F-8FC4-56BD9AA31F97Q37556076-9B616761-0249-454D-9D50-CC9CAA109266Q38179039-9257E0B6-5FEC-44BD-AFEB-10EFC6B5A54BQ42353384-E228EDE4-38D4-45D7-BF97-765DAE616B04Q47856782-4596EB87-0CD9-486F-BA9C-F69F4DB87084Q53434420-29AA663F-9AD5-4A50-8834-4FEBC1DD4046Q56832283-97BE3228-7B6A-411D-AB34-175F06784AB9
P2860
Zoledronic Acid and renal toxicity: data from French adverse effect reporting database.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Zoledronic Acid and renal toxicity: data from French adverse effect reporting database.
@ast
Zoledronic Acid and renal toxicity: data from French adverse effect reporting database.
@en
type
label
Zoledronic Acid and renal toxicity: data from French adverse effect reporting database.
@ast
Zoledronic Acid and renal toxicity: data from French adverse effect reporting database.
@en
prefLabel
Zoledronic Acid and renal toxicity: data from French adverse effect reporting database.
@ast
Zoledronic Acid and renal toxicity: data from French adverse effect reporting database.
@en
P2093
P2860
P356
P1476
Zoledronic Acid and renal toxicity: data from French adverse effect reporting database.
@en
P2093
Aline Munier
Marie-Josephe Jean-Pastor
Michel Andrejak
Michel Biour
Nathalie Bernard
Sophie Gautier
Valerie Gras
Ziad Massy
P2860
P304
P356
10.1345/APH.1E589
P407
P577
2005-06-14T00:00:00Z